Ken Fisher’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.36M | Sell |
1,190,896
-16,123
| -1% | -$84K | ﹤0.01% | 462 |
|
|
2025
Q4 | $7.42M | Sell |
1,207,019
-71,908
| -6% | -$521K | ﹤0.01% | 425 |
|
|
2025
Q3 | $9.25M | Sell |
1,278,927
-15,895
| -1% | -$94.4K | ﹤0.01% | 416 |
|
|
2025
Q2 | $6.88M | Buy |
1,294,822
+219,607
| +20% | +$1.3M | ﹤0.01% | 441 |
|
|
2025
Q1 | $9.54M | Buy |
1,075,215
+170,006
| +19% | +$2.04M | ﹤0.01% | 417 |
|
|
2024
Q4 | $12.4M | Buy |
905,209
+302,367
| +50% | +$5.58M | ﹤0.01% | 408 |
|
|
2024
Q3 | $16.5M | Buy |
602,842
+195,094
| +48% | +$5.28M | 0.01% | 366 |
|
|
2024
Q2 | $9.97M | Buy |
407,748
+19,401
| +5% | +$426K | ﹤0.01% | 416 |
|
|
2024
Q1 | $8.28M | Buy |
388,347
+230,378
| +146% | +$4.95M | ﹤0.01% | 445 |
|
|
2023
Q4 | $3.02M | Buy |
157,969
+15,313
| +11% | +$265K | ﹤0.01% | 547 |
|
|
2023
Q3 | $2.29M | Sell |
142,656
-27,540
| -16% | -$524K | ﹤0.01% | 611 |
|
|
2023
Q2 | $3.95M | Sell |
170,196
-13,828
| -8% | -$302K | ﹤0.01% | 574 |
|
|
2023
Q1 | $4.27M | Sell |
184,024
-6,359
| -3% | -$129K | ﹤0.01% | 562 |
|
|
2022
Q4 | $2.76M | Buy |
190,383
+64,276
| +51% | +$1.2M | ﹤0.01% | 601 |
|
|
2022
Q3 | $2.41M | Buy |
126,107
+54,250
| +75% | +$1.24M | ﹤0.01% | 548 |
|
|
2022
Q2 | $1.31M | Buy |
71,857
+328
| +0.5% | +$6.81K | ﹤0.01% | 587 |
|
|
2022
Q1 | $1.8M | Sell |
71,529
-14,702
| -17% | -$376K | ﹤0.01% | 564 |
|
|
2021
Q4 | $2.38M | Buy |
86,231
+27,464
| +47% | +$796K | ﹤0.01% | 541 |
|
|
2021
Q3 | $1.9M | Buy |
58,767
+5,013
| +9% | +$166K | ﹤0.01% | 541 |
|
|
2021
Q2 | $1.64M | Sell |
53,754
-324
| -0.6% | -$9.36K | ﹤0.01% | 554 |
|
|
2021
Q1 | $1.65M | Buy |
54,078
+1,024
| +2% | +$29.1K | ﹤0.01% | 553 |
|
|
2020
Q4 | $1.05M | Buy |
53,054
+3,255
| +7% | +$52.6K | ﹤0.01% | 590 |
|
|
2020
Q3 | $649K | Sell |
49,799
-11,907
| -19% | -$151K | ﹤0.01% | 612 |
|
|
2020
Q2 | $700K | Buy |
61,706
+37
| +0.1% | +$525 | ﹤0.01% | 615 |
|
|
2020
Q1 | $882K | Buy |
61,669
+18
| +0% | +$380 | ﹤0.01% | 550 |
|
|
2019
Q4 | $1.68M | Sell |
61,651
-119,504
| -66% | -$3.29M | ﹤0.01% | 517 |
|
|
2019
Q3 | $5.19M | Buy |
181,155
+43,225
| +31% | +$1.26M | 0.01% | 432 |
|
|
2019
Q2 | $3.83M | Buy |
137,930
+7,255
| +6% | +$205K | ﹤0.01% | 463 |
|
|
2019
Q1 | $4.34M | Sell |
130,675
-1,737
| -1% | -$52.9K | 0.01% | 434 |
|
|
2018
Q4 | $3.85M | Buy |
132,412
+4,141
| +3% | +$149K | 0.01% | 443 |
|
|
2018
Q3 | $5.9M | Buy |
128,271
+10,185
| +9% | +$453K | 0.01% | 404 |
|
|
2018
Q2 | $4.41M | Buy |
118,086
+4,797
| +4% | +$162K | 0.01% | 445 |
|
|
2018
Q1 | $3.35M | Sell |
113,289
-7,023
| -6% | -$238K | ﹤0.01% | 473 |
|
|
2017
Q4 | $4.13M | Hold |
120,312
| – | – | 0.01% | 446 |
|
|
2017
Q3 | $4.35M | Buy |
120,312
+59,301
| +97% | +$1.69M | 0.01% | 412 |
|
|
2017
Q2 | $1.58M | Hold |
61,011
| – | – | ﹤0.01% | 501 |
|
|
2017
Q1 | $1.17M | Buy |
61,011
+1,280
| +2% | +$22.7K | ﹤0.01% | 497 |
|
|
2016
Q4 | $996K | Sell |
59,731
-32,650
| -35% | -$591K | ﹤0.01% | 508 |
|
|
2016
Q3 | $1.9M | Buy |
92,381
+145
| +0.2% | +$3.68K | ﹤0.01% | 467 |
|
|
2016
Q2 | $2.96M | Buy |
92,236
+2,453
| +3% | +$85.2K | 0.01% | 423 |
|
|
2016
Q1 | $3.5M | Buy |
89,783
+8
| +0% | +$301 | 0.01% | 391 |
|
|
2015
Q4 | $3.88M | Hold |
89,775
| – | – | 0.01% | 375 |
|
|
2015
Q3 | $3.37M | Buy |
89,775
+1,725
| +2% | +$61.2K | 0.01% | 363 |
|
|
2015
Q2 | $2.99M | Hold |
88,050
| – | – | 0.01% | 367 |
|
|
2015
Q1 | $3.12M | Sell |
88,050
-283
| -0.3% | -$10.1K | 0.01% | 361 |
|
|
2014
Q4 | $3.01M | Buy |
+88,333
| New | +$3.13M | 0.01% | 360 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
Ken Fisher's MYGN Position: Q1 2026 in Review
Ken Fisher reduced its Myriad Genetics (MYGN) stake by 1.3% in Q1 2026, selling an estimated $84K and leaving 1,190,896 shares worth $5.36M. The position accounts for ﹤0.01% of the portfolio, ranked #462.
Ken Fisher first reported a position in MYGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $16.5M in Q3 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- Ken Fisher held 1,190,896 shares of Myriad Genetics worth $5.36M as of Q1 2026.
- Ken Fisher sold 16,123 Myriad Genetics shares in Q1 2026, an estimated $84K.
- Myriad Genetics made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #462 holding.
- Ken Fisher first reported a position in Myriad Genetics in Q4 2014 and has held it in 46 quarters since.
- Ken Fisher's Myriad Genetics position peaked at $16.5M in Q3 2024.
- 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.